News | December 30, 2022
Cipla EU to invest € 15 million in Ethris
Cipla and Ethris partner for the development of mRNA-based therapies
Cipla and Ethris partner for the development of mRNA-based therapies
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
Post the sale, Patel family has become the single largest promoter shareholder in the company
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The investment will enable the company to enter European markets as well as enhance margins in current markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
